The Department’s decision confirms what CPA has consistently warned: Chinese solar companies have been illegally circumventing U.S. trade laws through Southeast Asian shell operations, flooding the U.S. market with dumped and subsidized products directly harming the domestic solar manufacturing industry.
The Department of Defense designated CATL as a “Chinese military company” under Section 1260H of the National Defense Authorization Act on January 7. Their concern: CATL’s advanced lithium-ion batteries may one day be used to power China’s submarine fleet, replacing older battery models.
Tariffs on pharmaceutical companies isn’t just good economic policy — it benefits national security and public health.
Imports did not vanish, but their growth rate was flat at zero percent in February compared to January after nearly two months of importers rushing in orders ahead of tariffs. February goods and services imports were $401 billion, a statistically insignificant change from January, the Bureau of Economic Analysis said.
This legislative initiative aligns with CPA’s commitment to ensuring that U.S. capital does not inadvertently support adversarial regimes that undermine America’s economic and national security interests.
Members of the House Ways and Means Committee gave U.S. Trade Representative Jamieson Greer a piece of their mind on Wednesday during a four-and-a-half-hour hearing—double the time he spent with the Senate Finance Committee the day before.
Is China a peer competitor in the space race? On some fronts, the answer is yes. In others, the concern is that China is moving up the value chain so quickly that its companies may soon out-price American firms across the developing world.
The Trump administration is not backing down from its America First trade agenda, and Congress has granted the executive branch the authority to use emergency powers to impose tariffs in support of that agenda, U.S. Trade Representative Jamieson Greer told the Senate Finance Committee in a hearing on Tuesday.
CPA remains unwavering in our commitment to rebuilding U.S. industry and supporting American workers. China’s latest move only proves that our efforts are making an impact—and we will not back down.
The United States is amid a dangerous drug shortage that endangers patients, undermines our health care system and exposes a deep vulnerability to national security. America’s overwhelming reliance on foreign manufacturers for generic drugs is at the center of it.
